Table 1 Demographic characteristics of the study participants.
Characteristics | Total | Uninfected | Breakthrough infection | Reinfection |
|---|---|---|---|---|
No. of participants | 876 | 180 | 599 | 97 |
Sex (n, %) | ||||
Male | 272 (31.1%) | 67 (37.2%) | 176 (29.4%) | 29 (29.9%) |
Female | 604 (68.9%) | 113 (62.8%) | 423 (70.6%) | 68 (70.1%) |
Age (median, IQR) | 21 (21–22) | 21 (21–22) | 21 (21–22) | 21 (21–22) |
Vaccine status (n, %) | ||||
Two doses | 3 (0.3%) | NA | 2 (0.3%) | 1 (1.0%) |
Three doses | 870 (99.3%) | 179 (99.4%) | 595 (99.3%) | 96 (99.0%) |
Four doses | 3 (0.3%) | 1 (0.6%) | 2 (0.3%) | NA |
Primary Vaccination Regimen (n, %) | ||||
CoronaVac x2/BBIBP-CorV x2 | 853 (97.4%) | 175 (97.2%) | 585 (97.7%) | 93 (95.8%) |
ZF2001 × 2 × 3 | 22 (2.5%) | 5 (2.7%) | 12 (2.1%) | 4 (4.1%) |
CoronaVac x1 + ZF2001 × 1 | 1 (0.1%) | NA | 1 (0.1%) | NA |
Booster regimen (n, %) | ||||
CoronaVac x1/BBIBP-CorV x1 | 845 (96.5%) | 170 (94.4%) | 582 (97.2%) | 93 (95.8%) |
ZF2001 × 1 | 1 (0.1%) | NA | 1 (0.1%) | NA |
Ad5-nCoV x1 | 2 (0.2%) | 1 (0.5%) | 1 (0.1%) | NA |
mRNA x1 | 1 (0.1%) | NA | NA | 1 (1.0%) |
Treatment methods (n, %) | ||||
Home isolation | 542 (61.9%) | NA | 469 (78.3%) | 73 (75.3%) |
Outpatient or emergency | 151 (17.2%) | NA | 127 (21.2%) | 24 (24.7%) |
Hospitalization | 3 (0.3%) | NA | 3 (0.5%) | NA |
Interval between latest vaccination and sampling (median, IQR) | 678 (678–678) | 678 (678–678) | 678 (678–678) | 678 (678–678) |
